Results 1 to 10 of about 34,707 (260)

How much we know about bisphosphonate lesions [PDF]

Acta Stomatologica Naissi, 2016
Introduction: Bisphosphonate drugs are used in the treatment of the osteoporosis and malignant processes in the bone tissue. As a result of this use bisphosphonate lesions are formed in bone tissue and oral mucosis, which representing a remarkable ...
Pešić Zoran, Zarev Miloš, Ranđelović Jovana   +2 more
doaj   +2 more sources

Positive predictive values of the coding for bisphosphonate therapy among cancer patients in the Danish National Patient Registry

Clinical Epidemiology, 2012
Malene Schou Nielsson,1 Rune Erichsen,1 Trine Frøslev,1 Aliki Taylor,2 John Acquavella,2 Vera Ehrenstein11Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 2Center for Observational Research International, Amgen
Nielsson MS, Erichsen R, Frøslev T, Taylor A, Acquavella J, Ehrenstein V   +5 more
doaj   +1 more source

Bisphosphonate conjugation for bone specific drug targeting

Bone Reports, 2018
Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bone ...
Kristen B. Farrell, Alexander Karpeisky, Douglas H. Thamm, Shawn Zinnen   +3 more
doaj   +2 more sources

Regioselective ester cleavage during the preparation of bisphosphonate methacrylate monomers

Beilstein Journal of Organic Chemistry, 2011
New functional monomers bearing a methacrylate, a bisphosphonate function and, for most, an internal carboxylate group, were prepared for incorporation into copolymers with adhesive or anticorrosive properties.
Kamel Chougrani, Gilles Niel, Bernard Boutevin, Ghislain David   +3 more
doaj   +2 more sources

Does Bisphosphonate Increase the Sclerosis of Tibial Subchondral Bone in the Progression of Knee Osteoarthritis—A Propensity Score Matching Cohort Study Based on Osteoarthritis Initiative

Frontiers in Medicine, 2021
Bisphosphonate has great potential in KOA therapy, but whether the anti-resorption mechanism of bisphosphonate aggravates sclerosis of subchondral bone remains unclear.
Mingyang Li, Yong Nie, Yi Zeng, Yuangang Wu, Yuan Liu, Limin Wu, Jiawen Xu, Bin Shen   +7 more
doaj   +1 more source

Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients

Brazilian Journal of Otorhinolaryngology, 2022
Introduction: Medication-related osteonecrosis of the jaws is a severe complication of the use of antiresorptive and antiangiogenic therapy, with limited treatment options and great impact on patient’s quality pf life.
Aristilia Pricila Tahara Kemp, Vitor Hugo Candido Ferreira, Rafael Zancan Mobile, Thais Bianca Brandão, Laurindo Moacir Sassi, Amanda Zarpellon, Paulo Henrique Braz-Silva, Juliana Lucena Schussel   +7 more
doaj   +1 more source

Quality of Life Evaluation in Children With Osteogenesis Imperfecta After Giving Bisphosphonate Infusion in Dr. Soetomo Hospital Surabaya

Medical and Health Science Journal, 2020
INTRODUCTION Osteogenesis imperfecta (OI) or brittle bone disease is a connective tissue formation disorder that is generally characterized by bone fragility, osteopenia, blue sclera, dentinogenesis imperfecta (DI), and hearing loss.
Baskoro Kusumo Riswanto, Sulis Bayusentono   +1 more
doaj   +1 more source

Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells [PDF]

, 2020
Increasing attention has been paid to human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) in the field of cancer immunotherapy.
Senju, Hiroaki, Noda, Shuto, Okuno, Daisuke, Umeyama, Yasuhiro, Iwasaki, Masashi, Morita, Craig T., Mukae, Hiroshi, Sugiura, Yuki, Tagod, Mohammed S. O., Yamaguchi, Hiroyuki, Sakamoto, Noriho, Tanaka, Yoshimasa, Suematsu, Makoto, Tamura, Akihiro   +13 more
core   +1 more source

Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14 Years

JBMR Plus, 2021
Oral bisphosphonates are the primary medication for osteoporosis, but concerns exist regarding potential bone‐quality changes or low‐energy fractures.
Hartmut H Malluche, Jin Chen, Florence Lima, Lucas J Liu, Marie‐Claude Monier‐Faugere, David Pienkowski   +5 more
doaj   +1 more source

Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model

BMC Musculoskeletal Disorders, 2017
Background Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion.
Thomas Jakobsen, Søren Kold, Juan Shiguetomi-Medina, Jorgen Baas, Kjeld Soballe, Ole Rahbek   +5 more
doaj   +1 more source